Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Three-Stock Lunch: LLY, ETSY & PM
03:45pm, Tuesday, 20'th Jun 2023
Victoria Greene, G Squared Private Wealth chief investment officer, joins ‘Power Lunch' to discuss three stocks: Eli Lilly, Etsy and Philip Morris.
Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and orfor
Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement
12:56pm, Tuesday, 20'th Jun 2023
Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice T
Eli Lilly Buys DICE Therapeutics for $2.4 Billion
12:05pm, Tuesday, 20'th Jun 2023
Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.
Markets Fall at Midday, Pulled Lower by Energy Stocks
12:00pm, Tuesday, 20'th Jun 2023
Markets opened the shortened trading week on Tuesday, June 20, 2023 with losses as oil stocks sank along with the price of crude.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:16am, Tuesday, 20'th Jun 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover
09:02am, Tuesday, 20'th Jun 2023
Eli Lilly and Co (NYSE:LLY) said it has signed a definitive agreement to acquire DICE Therapeutics for $2.4 billion, sending shares of the biopharmaceutical company higher in pre-market trade. Under t
Cross-Sector Comparison: Is Estee Lauder A Better Pick Over LLY Stock?
09:00am, Tuesday, 20'th Jun 2023
Although these companies are from different sectors, we compare them because they have a similar operating income of $8-10 billion.
Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
08:29am, Tuesday, 20'th Jun 2023
Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.
Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push
07:06am, Tuesday, 20'th Jun 2023
Lilly said its acquisition of Dice for $48 a share would allow it to leverage the group's developing treatments for chronic diseases in immunology.
Dice Therapeutics rallies as it agrees to be bought by Lilly
07:01am, Tuesday, 20'th Jun 2023
Dice Therapeutics Inc. DICE stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. LLY for $48 a share in a deal that values the immunology company at about
Eli Lilly to buy Dice Therapeutics in $2.4 billion deal
07:00am, Tuesday, 20'th Jun 2023
Eli Lilly and Co will buy Dice Therapeutics Inc in an all-cash deal worth about $2.4 billion to boost its autoimmune drug portfolio, the companies said on Tuesday.
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says
03:23am, Tuesday, 20'th Jun 2023
The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to keep up with demand.
Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT
12:29pm, Monday, 19'th Jun 2023
Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.
Eli Lilly's migraine drug fails to meet main goal in post-approval study
12:28pm, Friday, 16'th Jun 2023
Eli Lilly said on Friday its drug Emgality did not meet the primary goal of superiority to Pfizer Inc's Nurtec ODT in prevention of episodic migraine in a post-approval study.
